Results 171 to 180 of about 872,057 (294)
Identification of plasma biomarkers in a PTZ-induced Sudden Unexpected Death-like model through integrated proteomics and metabolomics methods. [PDF]
Zheng G, Yang X, Chen Y, Zhang P, Nie Q.
europepmc +1 more source
Interventional therapies for chronic heart failure: An overview of recent developments
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
Mortality in female bodybuilding athletes. [PDF]
Vecchiato M +8 more
europepmc +1 more source
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk +12 more
wiley +1 more source
Calcium release channel deficiency syndrome in patients diagnosed with idiopathic ventricular fibrillation and decedents classified as sudden unexplained death in the young. [PDF]
Giammarino L +7 more
europepmc +1 more source
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri +12 more
wiley +1 more source
Leisure-time physical activity and risk of sudden cardiac death: a 28-year follow-up from the Copenhagen City Heart Study. [PDF]
Isozaki S +7 more
europepmc +1 more source
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao +27 more
wiley +1 more source
Sickle cell related cardiomyopathy and cardiovascular autonomic dysfunction. [PDF]
Hartnett J +8 more
europepmc +1 more source

